EUVIMEDOpdag EUVIMED
EditorialOpen access

Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence

Kevin V Houston, Jasmohan S Bajaj

Alimentary Pharmacology & Therapeutics · 2026-09 · 64 (5) · 681-682

DOI: 10.1111/apt.70809 ↗

At a glance

Editorial in Alimentary Pharmacology & Therapeutics, published online on 2026-06-21. Written by Kevin V Houston and 1 co-authors. Institution: Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA. Cited 2 times so far (Crossref); 10 references. The full text is freely available in PubMed Central. Funded by: U.S. Department of Veterans Affairs, CSRD VA, NIAAA NIH HHS.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Intet abstract tilgængeligt.

Authors and institutions

  • Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.

Funding

  • U.S. Department of Veterans Affairs
  • CSRD VA
  • NIAAA NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism

Cite

APA

Houston, K. V., & Bajaj, J. S. (2026). Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence. Alimentary Pharmacology & Therapeutics, 64(5), 681-682. https://doi.org/10.1111/apt.70809

Vancouver

Houston KV, Bajaj JS. Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence. Alimentary Pharmacology & Therapeutics. 2026;64(5):681-682. doi:10.1111/apt.70809

BibTeX
@article{Houston2026,
  author = {Houston, Kevin V and Bajaj, Jasmohan S},
  title = {Editorial: Rifaximin and the Gut–Liver–Brain Axis—Progress and Prudence},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {5},
  pages = {681--682},
  doi = {10.1111/apt.70809}
}
Start for free →